- Home » News and Events
NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic
May 16, 2022
The UpTempo Virtuoso platform streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation.
Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech
Apr 25, 2022
Catalent today announced that it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for $44.5 million.
Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility
Apr 21, 2022
The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.
Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe
Apr 5, 2022
Catalent today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
Catalent Biologics Completes $30 Million Project for Biopharmaceutical Development and Drug Product Manufacturing in Limoges, France
Mar 16, 2022
Catalent today announced the completion of a $30 million project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing
Dec 7, 2021
NurOwn is BrainStorm’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (PMS) and other neurodegenerative diseases.
Catalent’s Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus in Harmans, Maryland, Increases to $360M
Oct 26, 2021
Catalent today announced a $230 million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland, to meet growing customer demand.
Catalent Biologics Launches New GPEx® Lightning Cell Line Expression Technology to Shorten Drug Substance Development Timelines by up to Three Months
Jul 22, 2021
Leveraging Catalent’s proven GPEx® expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx Lightning combines innovative technologies to further shorten drug substance development timelines.
Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe
Jul 21, 2021
Catalent today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
ASGCT 25th Annual Meeting
Date: May 16-19, 2022
BIO International Convention 2022
Date: June 13-16, 2022
ISSCR Annual Meeting 2022
Date: June 15-18, 2022
CASSS Bioassays 2022
Date: July 19-21, 2022